Fig. 5From: Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case seriesa CT scan after treatment with an RNA oligonucleotide drug, MTL-CEBPA; 4.0 cm liver lesion b CT scan showing partial response after treatment with Lenvatinib for 8 weeks; 2.6 cm liver lesion c CT scan showing continued response after treatment with Lenvatinib for 20.4 weeks; 2.3 cm liver lesionBack to article page